Where regulation is weak, medicine transactions can be characterised by uncertainty over the drug quality and efficacy, with buyers shouldering the greater burden of risk in exchanges that are typically asymmetric. Drawing on in-depth interviews (N = 220) and observations of medicine transactions, plus interviews with regulators (N = 20), we explore how people in Ghana negotiate this uncertainty and come to trust a medicine enough to purchase or ingest it. We identify two mechanisms – attempts to mitigate uncertainty through seeking observable signs of quality and attempts to reduce informational asymmetry – that underpin cognitive assessments of a medicine's trustworthiness. However, these ‘cognitive’ forms of trust assessment have limited...
This study sought to lay bare, whether there was a high patronage for vended drugs and why, assess t...
Contains fulltext : 236952.pdf (Publisher’s version ) (Open Access
Regulatory science, which generates knowledge relevant for regulatory decision‐making, is different ...
Where regulation is weak, medicine transactions can be characterised by uncertainty over the drug qu...
Providing access to quality-assured medicines is a fundamental component of strengthening health sys...
In 2012, the WHO launched its Global Surveillance and Monitoring System (GSMS) for substandard and f...
Poor-quality medicines pose a significant challenge for health systems in low- to middle-income coun...
The disturbing emergence of substandard and fake drugs in Ghana is largely due to inadequate supervi...
This article presents an ethnographic study of regulatory decision-making regarding the cost-effecti...
This article is published under license to BioMed Central Ltd. This is an Open Access article distri...
This paper examines the processes of building cooperation in a context of sparse public-sector regul...
In this paper, we argue that understanding and addressing the problem of poor-quality medical produc...
© The Author(s) 2022. This article is licensed under a Creative Commons Attribution 4.0 Internationa...
Medicine adherence levels remain frustratingly static at 50% or lower (Sabaté, 2003). We believe th...
This article examines the “technological appraisals” carried out by the National Institute for Healt...
This study sought to lay bare, whether there was a high patronage for vended drugs and why, assess t...
Contains fulltext : 236952.pdf (Publisher’s version ) (Open Access
Regulatory science, which generates knowledge relevant for regulatory decision‐making, is different ...
Where regulation is weak, medicine transactions can be characterised by uncertainty over the drug qu...
Providing access to quality-assured medicines is a fundamental component of strengthening health sys...
In 2012, the WHO launched its Global Surveillance and Monitoring System (GSMS) for substandard and f...
Poor-quality medicines pose a significant challenge for health systems in low- to middle-income coun...
The disturbing emergence of substandard and fake drugs in Ghana is largely due to inadequate supervi...
This article presents an ethnographic study of regulatory decision-making regarding the cost-effecti...
This article is published under license to BioMed Central Ltd. This is an Open Access article distri...
This paper examines the processes of building cooperation in a context of sparse public-sector regul...
In this paper, we argue that understanding and addressing the problem of poor-quality medical produc...
© The Author(s) 2022. This article is licensed under a Creative Commons Attribution 4.0 Internationa...
Medicine adherence levels remain frustratingly static at 50% or lower (Sabaté, 2003). We believe th...
This article examines the “technological appraisals” carried out by the National Institute for Healt...
This study sought to lay bare, whether there was a high patronage for vended drugs and why, assess t...
Contains fulltext : 236952.pdf (Publisher’s version ) (Open Access
Regulatory science, which generates knowledge relevant for regulatory decision‐making, is different ...